-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since March 2020, the COVID-19 outbreak has challenged Spain's health system.
available therapies (antimalarial drugs, antiviral drugs, biologics) are based on clinical case observation or basic scientific data.
study aims to characterize the characteristics of patients with COVID-19 severe illness and the effects of different treatment methods on clinical prognosis.
a retrospective, single-center observational study, the researchers collected sequencing data from adult patients admitted to the University Hospital of Madrid in Quronsalud.
were included in patients who had tested positive for microbiology (nasal swab RT-PCR) or were epidemiologically diagnosed with severe COVID-19.
comparing the demographics, underlying diseases, laboratory data, clinical outcomes, and treatment of surviving and non-living patients.
mortality rates for patients of all ages were 10 March - 15 April 2020, with a total of 607 patients included.
age of 69 (65 per cent male).
most common complications were hypertension (46.94%), diabetes (16.16%), chronic heart disease (22.62%) and chronic respiratory disease (19.39%).
141 patients (23.2%) died.
In multivariate models, older patients with elevated toad monotherapy, elevated C-reactive proteins upon hospitalization, D-D-djusts and 2.5 ?g/mL, diabetes, or PaO2/FiO2 at hospital were associated with an increased risk of death.
Only cyclosporine was associated with a significant reduction in mortality in the cumulative in-hospital mortality-specific treatment drugs (toad monoantigen, glucosin, lopinevir/litonave, hydroxychloroquine, cyclosporine) that were not treated with cyclosporine.
in a real clinical environment, inhibiting the calcium-tuned phosphatase inflammatory path path, NF-T, can reduce the COVID-19 super-inflammatory stage.
findings may have some guiding significance for the treatment of the disease and may facilitate the design of new clinical trials for patients with COVID-19 severe illnesses.
.